Polymorphisms in genes involved in nervous system function, NFATC1, NFATC4, and EDN1 were associated with CIPN in 646 myeloma patients treated with bortezomib (52), as were TCF4, DYNC1I1, and GJE1 in 139 myeloma patients treated with bortezmib (55). This evidence concerns the gene TCF4 and plasma cell myeloma.